On November 8, 2024, the U.S. Department of Labor (DOL) issued an opinion letter (FMLA2024-01-A) providing important guidance on the use of Family and Medical Leave Act (FMLA) leave for employees undergoing treatment for serious health conditions as part of clinical trials. As the healthcare landscape evolves, understanding the implications of this guidance is crucial for employers striving to support their workforce while ensuring compliance with federal labor laws.
The DOL clarified that employees are permitted to use FMLA leave for treatment related to serious health conditions when that treatment is part of a clinical trial. This includes various medical interventions—such as experimental treatments, placebos, or new drugs—provided the employee meets all other FMLA eligibility requirements. The letter underscores the importance of enabling employees to participate in clinical trials without fear of job loss or financial instability. Many potential participants, particularly those from underserved communities, may hesitate to enroll in clinical trials due to concerns about taking time off work. By affirming that FMLA leave applies to clinical trial participation, the DOL aims to promote equitable access to critical medical research.
One key point in the opinion letter is the broad definition of “treatment” under FMLA regulations. This definition includes various medical interventions beyond standard care, such as prescription medications and specialized therapies. The DOL emphasized that the experimental nature or unproven effectiveness of the treatment does not disqualify it from being considered permissible under the FMLA. This interpretation reflects the Department’s intent to avoid discouraging employees from seeking necessary medical interventions.
Employers must understand their responsibilities under this guidance. When an employee requests FMLA leave for a serious health condition, employers can require certification to support the leave request. This certification should confirm the medical necessity of the leave but must not require employees to disclose specific details about their treatment plans or medications. Instead, employers should focus on the general nature of the treatment, ensuring employees’ confidentiality regarding their health conditions.
Next Steps
This opinion letter represents a significant step toward promoting employee health and facilitating participation in clinical trials. Employers who adapt their HR practices in response to this guidance can foster a supportive workplace environment while ensuring compliance with federal regulations. To comply with the DOL’s guidance and support employees participating in clinical trials, employers should take several proactive steps:
- Educate HR and Management: Provide training for HR personnel and managers to ensure they understand the implications of the opinion letter. Emphasize the importance of handling FMLA requests with sensitivity and confidentiality, particularly when health conditions and clinical trials are involved.
- Foster Open Communication: Create a workplace environment where employees feel comfortable requesting leave related to health conditions or clinical trials. Providing communication about FMLA leave availability reinforces employees’ understanding of their rights and encourages them to seek necessary medical treatments.
- Streamline Certification Processes: Establish clear procedures for collecting and reviewing medical certifications for FMLA leave. These procedures should align with the DOL’s guidelines, focusing on general information about the employee’s serious health condition and the need for treatment.
- Conduct Regular HR Audits: Periodically audit HR practices to ensure compliance with FMLA regulations and the latest DOL guidance.
By establishing clear communication, education, and robust policies around FMLA leave, employers can help employees pursue necessary medical treatments without fear of jeopardizing their job security. This approach benefits employees by improving access to care and benefits employers by enhancing workplace morale and demonstrating a commitment to health and well-being.
HR Works Can Help
Managing employee leaves of absence is overwhelming, and the various laws can be difficult to navigate, especially when leave is not your primary focus. The experts at HR Works can manage the complexities of compliance when it comes to federal and state leave laws and more. To learn more about these services and how to leverage our compliance expertise and support, please contact us at info@hrworks-inc.com or call 1-877-219-9062.
